News und Analysen
![Veeva Enables CROs to Build Studies Faster with Vault EDC](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Enables CROs to Build Studies Faster with Vault EDC
Veeva Systems (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC. As part of the CRO partner program, CROs are trained and receive best
![Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
Veeva Systems (NYSE: VEEV) today announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials. Vault Site Connect automates the flow of
![Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials
Veeva Systems (NYSE: VEEV) today announced MyVeeva, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to
![Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for
![Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!
Gilead Sciences (WKN: 885823), CytoDyn (WKN: A0YHA5) und Evotec (WKN: 566480) – die Aktien der drei Pharmaunternehmen sind in diesem Jahr – trotz oder gerade wegen Corona – vergleichsweise gut
![Pfizer Prices $4,000,000,000 Debt Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Prices $4,000,000,000 Debt Offering
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:
$750,000,000 aggregate principal amount of 0.800% notes due 2025
$1,000,000,000
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research
Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in
![Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer
![Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary
![Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three
![Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Humana Ranks #1 in J.D. Power Commercial Member Health Plan Study – in Florida and Texas
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it is ranked #1 in Florida and Texas in the 2020 J.D. Power ranking of Commercial member health plans. Humana has
![Humana’s Annual Report on Employee Well-Being Illustrates the Company’s Culture and Highlights Resiliency](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Humana’s Annual Report on Employee Well-Being Illustrates the Company’s Culture and Highlights Resiliency
Humana Inc. (NYSE: HUM) has released its latest annual report on employee well-being, which continues to show that passion for whole-person well-being, both inside and outside the workplace, can
![Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day on Monday, September 14, 2020 at 9:00 a.m. EDT. Pfizer postponed its Investor Day, originally scheduled
![New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the RBC Capital Markets
![Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral
Agilent Technologies Inc. (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge
![DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes
DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 (the “notes”) in a private
![Humana Specialty Pharmacy Wins National Award for Third Consecutive Year](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Humana Specialty Pharmacy Wins National Award for Third Consecutive Year
Humana Specialty Pharmacy has received the Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the third year in a row. The award, presented by Zitter Health Insights, a division
![Humana Announces Additional Bold Goal Communities in Cincinnati and Detroit](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Humana Announces Additional Bold Goal Communities in Cincinnati and Detroit
Humana Inc. (NYSE: HUM) announced today that Cincinnati, Ohio and Detroit, Michigan are the latest additions to its Bold Goal communities. The Bold Goal is Humana’s population health strategy to
![DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes
DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior
![Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020
DexCom, Inc. (NASDAQ:DXCM) today announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. (the “Company”)
![Gilead Sciences: Remdesivir ist leider kein Allheilmittel](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Gilead Sciences: Remdesivir ist leider kein Allheilmittel
Gilead Sciences (WKN: 885823) ist, langfristig betrachtet, eine der größten Erfolgsgeschichten im Biotechsektor. So gelang es dem, zwischenzeitlich zu einem Konzern herangewachsenen, Unternehmen
![Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT. The purpose